News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
704,896 Results
Type
Article (61861)
Company Profile (319)
Press Release (642716)
Section
Business (199944)
Career Advice (2931)
Deals (34672)
Drug Delivery (105)
Drug Development (84831)
Employer Resources (161)
FDA (17288)
Job Trends (15205)
News (346687)
Policy (34760)
Tag
Academia (2845)
Alliances (51896)
Alzheimer's disease (1335)
Approvals (17195)
Artificial intelligence (146)
Bankruptcy (339)
Best Places to Work (11839)
Biotechnology (224)
Breast cancer (127)
Cancer (1141)
Cardiovascular disease (108)
Career advice (2465)
Cell therapy (265)
Clinical research (67080)
Collaboration (403)
Compensation (167)
COVID-19 (2743)
C-suite (99)
Data (1145)
Diabetes (162)
Diagnostics (6344)
Drug pricing (94)
Earnings (78089)
Employer resources (143)
Events (103336)
Executive appointments (315)
FDA (17836)
Funding (362)
Gene therapy (196)
GLP-1 (659)
Government (4759)
Healthcare (19516)
Infectious disease (2836)
Inflammatory bowel disease (121)
Interviews (555)
IPO (15886)
Job creations (3777)
Job search strategy (2043)
Layoffs (437)
Legal (8090)
Lung cancer (185)
Manufacturing (184)
Medical device (13282)
Medtech (13286)
Mergers & acquisitions (18859)
Metabolic disorders (444)
Neuroscience (1637)
NextGen Class of 2024 (6983)
Non-profit (4924)
Northern California (1451)
Obesity (251)
Opinion (238)
Patents (107)
People (55632)
Phase I (20590)
Phase II (29330)
Phase III (22253)
Pipeline (463)
Postmarket research (2964)
Preclinical (9019)
Radiopharmaceuticals (237)
Rare diseases (243)
Real estate (6010)
Regulatory (23298)
Research institute (2566)
Resumes & cover letters (476)
Southern California (1287)
Startups (3591)
United States (13420)
Vaccines (635)
Weight loss (200)
Date
Today (129)
Last 7 days (809)
Last 30 days (3774)
Last 365 days (36347)
2024 (33253)
2023 (40435)
2022 (51631)
2021 (56197)
2020 (55144)
2019 (48301)
2018 (36651)
2017 (33916)
2016 (33634)
2015 (38733)
2014 (31998)
2013 (27964)
2012 (29487)
2011 (29679)
2010 (28645)
Location
Africa (1013)
Arizona (160)
Asia (42253)
Australia (7219)
California (3283)
Canada (1255)
China (252)
Colorado (149)
Connecticut (158)
Europe (95791)
Florida (454)
Georgia (114)
Illinois (363)
Indiana (197)
Maryland (578)
Massachusetts (2591)
Michigan (162)
Minnesota (254)
New Jersey (956)
New York (960)
North Carolina (771)
Northern California (1451)
Ohio (140)
Pennsylvania (826)
South America (1307)
Southern California (1287)
Texas (457)
Utah (94)
Washington State (358)
704,896 Results for "centers for disease control and prevention cdc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Vaccines
CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for adults aged 75 and older, and in seniors 60 to 74 years who are at risk of severe disease.
October 25, 2024
·
2 min read
·
Tristan Manalac
Vaccines
CDC Panel Recommends Merck and Pfizer Pneumococcal Vaccines for Adults Aged 50–64
The CDC’s Advisory Committee on Immunization Practices on Wednesday backed the use of Merck’s Capvaxive and Pfizer’s Prevnar 20 in adults between 50-64 years of age, opening a bigger market for the respective companies.
October 24, 2024
·
2 min read
·
Tristan Manalac
Policy
CDC Narrows RSV Vaccine Recommendations for Seniors
New recommendations from the Centers for Disease Control and Prevention call for the use of respiratory syncytial virus vaccines in adults aged 75 and older, but limited its use in 60- to 74-year-olds.
June 27, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
Merck, known as MSD outside of the United States and Canada, announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices unanimously voted to recommend CAPVAXIVE™ as an option for adults 65 years of age and older for pneumococcal vaccination.
June 27, 2024
·
6 min read
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Policy
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
·
2 min read
·
Tristan Manalac
Genetown
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised actions taken by the U.S. Centers for Disease Control and Prevention (CDC) aimed at optimizing hospital sepsis programs in the United States.
August 28, 2023
·
6 min read
Drug Development
AstraZeneca, Sanofi’s Beyfortus 90% Effective at Preventing RSV Hospitalizations: CDC
AstraZeneca and Sanofi’s respiratory syncytial virus immunizing antibody Beyfortus reached effectiveness of 90% against infection-related hospitalization in infants, according to the Centers for Disease Control and Prevention.
March 8, 2024
·
2 min read
·
Tristan Manalac
BioMidwest
HabitNu Awarded $14M in CDC Funding to Fight America’s Diabetes Epidemic
HabitNu, the health and wellness company that connects community-based Diabetes Prevention Program (DPP) providers with those in need of services, was awarded a $14M, five-year cooperative agreement with the Centers for Disease Control (CDC).
March 7, 2024
·
2 min read
Vaccines
GSK Lowers Full-Year Vaccine Guidance After Disappointing Q2 Sales, CDC RSV Guidelines
Systemic administrative and policy challenges, including updated CDC guidelines regarding the use of RSV shots in seniors, have forced GSK to lower its 2024 outlook for its vaccines business.
July 31, 2024
·
2 min read
·
Tristan Manalac
1 of 70,490
Next
